Chu et al. employed a liposome-based delivery system to develop polymeric neoantigen nanovaccines that target APCs in TDLNs, demonstrating enhanced cross-presentation and subsequent activation of neoantigen-specific CD8+ T cell responses in the melanoma mice[210]. Here, CD8A is linked to melanoma.